At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 254 enrolled
Drug / intervention
VT-1161 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of VT-1161 Oral Tablets in the Treatment of Patients With Recurrent Vulvovaginal Candidiasis
In Brief
A Phase 2 clinical trial evaluating VT-1161 and Placebo for Recurrent Vulvovaginal Candidiasis. Completed, enrolled 254 participants across 32 sites.
Detailed Summary
VT-1161 is a novel, oral inhibitor of fungal lanosterol demethylase (CYP51). In vitro and in vivo pharmacology studies have demonstrated that VT-1161 is highly active against Candida albicans and also non-albicans Candida species that cause vulvovaginal candidiasis. VT-1161 is highly selective for fungal CYP51, and data suggests that it may avoid the side-effect profile that limits the use of commonly prescribed antifungal agents for the treatment of recurrent yeast infections.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRecurrent Vulvovaginal Candidiasis
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedOct 2014
Enrollment StartFeb 2015
Primary CompletionNov 2016
TodayJul 2026
First PostedOct 17, 2014
Enrollment StartFeb 10, 2015
Primary CompletionNov 9, 2016
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 11.7 years ago
Interventions
VT-1161drug
Placebodrug